We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Invitae Corp USD0.0001

Sell:$0.0003 Buy:$0.0003 Change: $0.0001 (25.00%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $0.0001 (25.00%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $0.0001 (25.00%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Contact details

1400 16Th Street
United States
+1 (0415) 3747782

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Market cap:
Shares in issue:
286.49 million
Health Care Services
Off Exchange
US dollar

Key personnel

  • Kenneth Knight
    President, Chief Executive Officer, Director
  • Ana Schrank
    Chief Financial Officer, Chief Accounting Officer
  • David Sholehvar
    Chief Operating Officer
  • Thomas Brida
    Chief Compliance Officer, General Counsel, Secretary
  • Veteran Robert Guigley
    Chief Commercial Officer
  • W. Michael Korn
    Chief Medical Officer - Oncology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.